Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit

Sanguinetti, Alessandro; Polistena, Andrea; Lucchini, Roberta; Monacelli, Massimo; Galasse, Sergio; Avenia, Stefano; Triola, Roberta; Bugiantella, Walter; Cirocchi, Roberto; Rondelli, Fabio; Avenia, Nicola

doi:10.1016/j.ijscr.2016.02.004

Cited by 38 publications

(33 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the literature on the treatment of MBC, modified radical mastectomy is generally preferred to breast conservation surgery (BCS) [8], [9]. Some others reported more radical surgical approach; 71% of patients in Sanguinetti paper treated with more radical treatment such as radical mastectomy (RM) [10].…”

Section: Introductionmentioning

confidence: 99%

Male breast cancer: Modified radical mastectomy or breast conservation surgery? A case report and review of the literature

Giunta

Rossi

Toia

et al. 2017

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

IntroductionMale breast cancer (MBC) is a rare disease that accounts for <1% of breast cancer cases. The most common treatment is modified radical mastectomy (MRM). Recently, breast conservative surgery (BCS) is getting popular for MBC treatment. We report a case and reviewed the literature to investigate whether emerging BCS can be considered as an alternative of a more radical surgery.Presentation of caseA 46 y.o. patient, presented with a painless left breast lump over a period of six months. The patient underwent a quadrantectomy at another institution. Pathology revealed an intraductal carcinoma in close proximity to the margins of excision. Adjuvant hormonal therapy was proposed to the patient, who refused and was referred to our Institution. We performed a MRM and a sentinel lymph node biopsy (SLNB). A contralateral breast liposuction and an adenectomy were also performed. The patient underwent also a nipple-areolar complex reconstruction. The patient didn’t receive adjuvant therapy.DiscussionBoth oncological safety and satisfactory cosmetic outcomes are the goals of MBC treatment. No specific guidelines for MBC treatment have been proposed. MRM is currently the surgical gold standard of MBC (approximately 70% of all cases). Some authors reported that male BCS associated with radiation therapy is a feasible alternative MRM. Taking into account data from the literature and considering the previous surgery, in the case we report, we offered a MRM, SLNB and a contralateral breast symmetrization.ConclusionMRM with SLNB and reconstruction of male breast asymmetry should be still considered as the treatment of choice of MBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Male breast cancer: Modified radical mastectomy or breast conservation surgery? A case report and review of the literature

Giunta

Rossi

Toia

et al. 2017

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

“…The immunohistochemical study showed an intense and diffuse tumor cells staining for estrogen receptor, a moderate and partial expression for progesterone receptor, which is consistent with previous studies. From the fact that our patient has no factor favouring and shows a Hercep Test of score 3+ (HER2 positive), while the most of the male breast carcinoma BRCA1-related are negative HER2 (4) , we can assume that in this case male breast cancer is secondary to the treatment by the decapeptyl. Radical mastectomy was more commonly used in older case series, likely reflecting both practice patterns (radical and modified radical mastectomies) and later stage at diagnosis of patients in the older series (3) , despite the fact that retrospective studies have shown that the prognosis is the same as for less invasive surgery (15) .…”

Section: Discussionmentioning

confidence: 84%

“…The risk factors are multiple and varied but the genetic factor remains the most important (mutations in BRCA1 and/or BRCA2 genes) (4) . The clinical presentation of the disease differs slightly in men.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Second Primary Breast Cancer in Men with Prostate Adenocarcinoma Treated by Decapeptyl: A Case Report

Nachite¹,

Elouariachi²,

Ochi³

et al. 2017

IAM

View full text Add to dashboard Cite

Introduction: Breast cancer in men is a rare disease, especially in association with prostate cancer. Risk factors are multifactorial and include environmental factors, genetic susceptibility and hormonal treatments. Decapeptyl an analogue to gonadorelin (GnRH-agonist) used, in association with surgery, in treatment for prostate adenocarcinoma may likely cause breast cancer in these patients. Case presentation: A 56-year-old man followed for a non-metastatic prostate adenocarcinoma presents after ten months of treatment with Decapeptyl a breast tumor. After resection of the breast carcinoma, the histological find an invasive breast carcinoma no special type (NST) grade II of SBR. The immunohistochemical study of the tumor specimen was positive for estrogen receptor (70 to 100 % of tumoral surface), progesterone receptor (50 to 70 % of tumoral surface) and Hercep Test of score 3+ (HER 2 positive). Discussion: The risk of male breast cancer with long-term steroidal anti-androgens is well documented; however, the risk of male breast cancer with a synthetic gonadotropin-releasing hormone (GnRH) is extremely rare. Only one case presenting a breast cancer after treatment with leuprolide (GnRH-agonist) has been reported in the literature, and obviously this is the first case of mammary carcinoma in men secondary to treatment with Decapeptyl. The majority of these breast cancers in men are invasive breast carcinoma no-special type or unclassified. Other types of tumors are very rare. Decapeptyl contains the active ingredient Triptorelin used to treat prostate cancer, which normally has to decrease breast cancer risk, but in this case it appears to be involved in the appearance of breast carcinoma. Conclusion: This report illustrates a case of invasive breast carcinoma in a man followed for prostate adenocarcinoma and treated by Decapeptyl. This treatment seems to be the principal risk factor involved in the appearance of a second primary tumor in men diagnosed with prostate cancer.

show abstract

“…Some researchers observe that disparities exist between the knowledge, treatment and management of female and male breast cancer. They argue that MBC is not properly understood, with some studies indicating that MBC is physically and psychologically different from FBC, and therefore affects men differently to women (Johansson et al 2014;Robinson et al 2008;Ruddy et al 2013;Sanguinetti et al 2016). According to Johansson et al (2014: 527), most of the understanding of MBC has been extrapolated from knowledge of FBC, and even though differences (and some similarities) have been reported, the same information is used to determine management strategies.…”

Section: Disparities Between Female and Male Breast Cancer Messagesmentioning

confidence: 99%

Communicating Male Breast Cancer: Knowledge and Awareness Among Some South African Youth

Motloutsi

Lubinga

2017

Comm

View full text Add to dashboard Cite

show abstract

Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit

Cited by 38 publications

References 36 publications

Male breast cancer: Modified radical mastectomy or breast conservation surgery? A case report and review of the literature

Male breast cancer: Modified radical mastectomy or breast conservation surgery? A case report and review of the literature

Second Primary Breast Cancer in Men with Prostate Adenocarcinoma Treated by Decapeptyl: A Case Report

Communicating Male Breast Cancer: Knowledge and Awareness Among Some South African Youth

Contact Info

Product

Resources

About